Development

Gerresheimer invests up to 94 million Dollar in US production facility

Retrieved on: 
Tuesday, August 9, 2022 - 6:00am
Office of the Assistant Secretary for Preparedness and Response, Glass, Pharma, Joint Program Executive Office Chemical and Biological Defense, Radiation, CEO, ASPR, Office of Inspector General, U.S. Department of Health and Human Services, Assistant, BARDA, Growth, Investment, Cosmetics, AG, Department, Army, Government, DOD, Biomedical Advanced Research and Development Authority, COVID-19, U.S. Department of Defense Strategy for Operating in Cyberspace, Infection, Acquisition, United States Department of Defense, ACC, GX, Army Contracting Command, HHS, Development, Administration, Pharmaceutical industry, Chemical substance

It will expand Gerresheimer's capacity by new vial forming lines, including dimensional inspection, annealing, cosmetic inspection and packaging.

Key Points: 
  • It will expand Gerresheimer's capacity by new vial forming lines, including dimensional inspection, annealing, cosmetic inspection and packaging.
  • BARDA has agreed to provide up to approximately 66 million US-Dollar to Gerresheimer AG for this project.
  • Under the agreement, Gerresheimer will increase its annual production capacity in Morganton, NC with interchangeable Type 1 vials(glass borosilicate and/or aluminosilicate) and Gx Elite Glass Vialscapability.
  • "Gerresheimer is honored to support the U.S. government in strengthening its pharmaceutical supply chain for current and future healthcare emergencies," said Dietmar Siemssen, CEO of Gerresheimer AG.

Gerresheimer invests up to 94 million Dollar in US production facility

Retrieved on: 
Tuesday, August 9, 2022 - 6:00am
Office of the Assistant Secretary for Preparedness and Response, Glass, Pharma, Joint Program Executive Office Chemical and Biological Defense, Radiation, CEO, ASPR, Office of Inspector General, U.S. Department of Health and Human Services, Assistant, BARDA, Growth, Investment, Cosmetics, AG, Department, Army, Government, DOD, Biomedical Advanced Research and Development Authority, COVID-19, U.S. Department of Defense Strategy for Operating in Cyberspace, Infection, Acquisition, United States Department of Defense, ACC, GX, Army Contracting Command, HHS, Development, Administration, Pharmaceutical industry, Chemical substance

It will expand Gerresheimer's capacity by new vial forming lines, including dimensional inspection, annealing, cosmetic inspection and packaging.

Key Points: 
  • It will expand Gerresheimer's capacity by new vial forming lines, including dimensional inspection, annealing, cosmetic inspection and packaging.
  • BARDA has agreed to provide up to approximately 66 million US-Dollar to Gerresheimer AG for this project.
  • Under the agreement, Gerresheimer will increase its annual production capacity in Morganton, NC with interchangeable Type 1 vials(glass borosilicate and/or aluminosilicate) and Gx Elite Glass Vialscapability.
  • "Gerresheimer is honored to support the U.S. government in strengthening its pharmaceutical supply chain for current and future healthcare emergencies," said Dietmar Siemssen, CEO of Gerresheimer AG.

Enthusiast Gaming Provides Update on Senior Management Team and Board of Directors

Retrieved on: 
Monday, August 8, 2022 - 10:00pm
The Co Founder, Love, Stikeman Elliott, Millennials, Defy Media, Industry, CEO, GLOBE, Content, Growth, SVP, Investment, Genz, TSX, Leadership, EGLX, Board, Hilltop Holdings Inc., Enthusiasm, Compliance, Marketing, General counsel, General manager, Company, Chairperson, Lists of video games, Element, NASDAQ, Enthusiast Gaming, Board of directors, Development, Ethics, Time, IPO, Video game, Management, JB, Engineering

LOS ANGELES, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (Enthusiast Gaming or the Company) (NASDAQ:EGLX; TSX:EGLX), an integrated gaming entertainment company, is pleased to provide the following update on its senior management team and Board of Directors.

Key Points: 
  • LOS ANGELES, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (Enthusiast Gaming or the Company) (NASDAQ:EGLX; TSX:EGLX), an integrated gaming entertainment company, is pleased to provide the following update on its senior management team and Board of Directors.
  • Bill is the Co-Founder of Addicting Games (acquired by Enthusiast Gaming in 2021) where he previously oversaw the companys operations, growth strategies, and product development.
  • Bill joined Enthusiast Gaming in 2020 and has been a key leader for the Company, building out its global direct sales organization.
  • Enthusiast Gaming is an integrated gaming entertainment company, building the largest media and content platform for video game and esports fans to connect and engage worldwide.

Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 8, 2022 - 9:05pm
High-risk pregnancy, Public health, GLOBE, Death, NS5A, Clinical trial, Research, Patient, Hospital, Final Analysis, Viral load, Atea, Development, Food, Combination therapy, Income, Omicron, Merck, Fever Dream, DENV, Safety, Doctor of Philosophy, Nasdaq, Pharmacokinetics, Alpha, European Medicines Agency, Protease, COVID-19, Virology, Vaccine, Infection, Immunodeficiency, RZR, Delta, Cash, Food and Drug Administration, Severe acute respiratory syndrome coronavirus 2, HCV, EMA, Dengue fever, FDA, BID, Ritonavir, Founder, Emergency Task Force (Toronto Police Service), Therapy, Income tax, Dengue virus, Personal income in the United States, Administration, Adult, Pharmaceutical industry, Life insurance, Vitro

New antivirals with improved profiles are urgently needed, said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.

Key Points: 
  • New antivirals with improved profiles are urgently needed, said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.
  • For dengue, we are currently enrolling two proof-of-concept trials for AT-752 and expect initial results in late 2022.
  • Operational planning for this trial is currently underway with the goal of initiation during the fourth quarter of 2022.
  • Results from the human challenge trial and initial results from the DEFEND-2 study are expected in the fourth quarter of 2022.

Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene

Retrieved on: 
Monday, August 8, 2022 - 9:05pm
FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Drug, NDA, Fentanyl, Biomedical Advanced Research and Development Authority, GLOBE, BARDA, Terminology, Media, PD, Absorption, United States Department of Health and Human Services, Department, Human services, Opioid overdose, Plasma, CDC, Administration, Risk, NASDAQ, PK, Drug overdose, Development, Food, File, Fast track (FDA), Pharmaceutical industry

SANTA MONICA, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc.(Opiant) (NASDAQ: OPNT) today announced that theBiomedical Advanced Research and Development Authority(BARDA) has awarded an additional approximately $2.1 millionto support OPNT003, nasal nalmefene, for the treatment of opioid overdose.

Key Points: 
  • SANTA MONICA, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc.(Opiant) (NASDAQ: OPNT) today announced that theBiomedical Advanced Research and Development Authority(BARDA) has awarded an additional approximately $2.1 millionto support OPNT003, nasal nalmefene, for the treatment of opioid overdose.
  • We greatly appreciate BARDAs support for OPNT003, saidRoger Crystal, M.D., President and Chief Executive Officer of Opiant.
  • Earlier awards from BARDA for $8.7 million, combined with a$7.4 milliongrant Opiant received from theNational Institute on Drug Abuse, have also supported the clinical development and U.S. regulatory submission of OPNT003.
  • Opiant Pharmaceuticals, Inc., the company that developed NARCAN Nasal Spray, is building a leadingfranchiseof new medicines to combat addictions and drug overdose.

Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 8, 2022 - 9:30pm
FDA, Intellectual property, Woman, U.S. Securities and Exchange Commission, Chimeric antigen receptor T cell, State Administrative Expenses, CAR, Part, Lung cancer, Forward-looking statement, Trial of the century, GLOBE, R, Technology, Cancer, Infection, Incidence, Security (finance), Research, Patient, Therapy, COVID-19, Company, Acquisition, Breast cancer, Form 10-K, Vaccine, Safety, ATOS, Esophageal cancer, Transfusion-related acute lung injury, Nasdaq, Severe acute respiratory syndrome coronavirus 2, Proceedings of the Institution of Mechanical Engineers, Part B, Development, Administration, Adult, Pharmaceutical industry, Renewable energy, Medical imaging, Lithium, Atossa, Endoxifen, G&A

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2022, and provides an update on recent company developments.

Key Points: 
  • SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2022, and provides an update on recent company developments.
  • The FDA has issued a clinical hold letter requesting additional information which Atossa plans to submit by the end of the third quarter 2022 and to initiate enrollment in the fourth quarter 2022.
  • For the quarter ended June 30, 2022, Atossa had no source of sustainable revenue and no associated cost of revenue.
  • Six Months Ended June 30, 2022 Financial Results (in thousands):
    For the six months ended June 30, 2022, Atossa had no source of sustainable revenue and no associated cost of revenue.

Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results

Retrieved on: 
Monday, August 8, 2022 - 9:05pm
DREAM, FDA, U.S. Securities and Exchange Commission, Technology, Sleep, Growth, SEC, Investment, BLAST, CCC, Security (finance), OSA, CE, Patient, Company, Acceleration, Research and development, Euronext, CET, NASDAQ, General officer, Research, IDE, Goal, Total, Development, Administration, Film, Pharmaceutical industry, Renewable energy, European

Revenue was 935,000 for the second quarter ending June 30, 2022, compared to 170,000 for the second quarter ending June 30, 2021.

Key Points: 
  • Revenue was 935,000 for the second quarter ending June 30, 2022, compared to 170,000 for the second quarter ending June 30, 2021.
  • Selling, General and Administrative expenses rose to 4.5 million for the second quarter of 2022, up from 3.9 million in the second quarter of 2021.
  • Total operating loss for the second quarter and first half of 2022 was 7.4 million and 14.7 million, respectively, versus 6.3 million and 11.6 million in the second quarter and first half of 2021, respectively.
  • Nyxoah realized a net loss of 5.0 million and 11.8 million for the second quarter and first half of 2022, respectively, compared to a net loss of 6.7 million and 12.4 million for the second quarter and first half of 2021, respectively.

Crowley Partners with EcoVadis for a More Transparent, Sustainable Value Chain

Retrieved on: 
Monday, August 8, 2022 - 4:45pm
Zero, Cloud, Johnson & Johnson, JPMorgan Chase, Carbon, Industry, Salesforce, Growth, Business, BASF, Environment, ESG, Program, Partnership, LVMH, Goal, Development, Ethics, Solution, UN, PricewaterhouseCoopers, Renewable energy, Risk management, Bridgestone, Unilever

JACKSONVILLE, Fla., Aug. 8, 2022 /PRNewswire-PRWeb/ -- Crowley has chosen international business sustainability ratings provider EcoVadis to assess its value chain for its suppliers' environmental, social and governance (ESG) impacts. A global provider of supply chain solutions, Crowley is the first U.S.-based company in maritime and logistics to partner with EcoVadis on its value chain solutions.

Key Points: 
  • Crowley partners with EcoVadis to asses ESG impacts throughout its value chain.
  • JACKSONVILLE, Fla., Aug. 8, 2022 /PRNewswire-PRWeb/ -- Crowley has chosen international business sustainability ratings provider EcoVadis to assess its value chain for its suppliers' environmental, social and governance (ESG) impacts.
  • A global provider of supply chain solutions, Crowley is the first U.S.-based company in maritime and logistics to partner with EcoVadis on its value chain solutions.
  • "Crowley has taken an essential step by including the value chain in their sustainability commitments," said David McClintock, Marketing Director at EcoVadis.

Omaha-Based MRI Medical Device Company, Bot Image, Receives FDA Clearance for Artificial Intelligence Software Used in Detection and Diagnosis of Prostate Cancer

Retrieved on: 
Monday, August 8, 2022 - 3:00pm
FDA, Multimedia, Prostate cancer, Intelligence, Manifest and latent functions and dysfunctions, CAD, CEO, Negotiation, Diagnosis, Technology, Ginkgo CADx, Incontinence, Liver disease, CT, Hospital, Classification, Software as a service, Radiology, Man, Patient, Stroke, Use, Prostate, Contract, Cade, VPN, Artificial intelligence, HIPAA, Software, Time, Development, MRI, Adoption, Medical imaging

OMAHA, Neb., Aug. 8, 2022 /PRNewswire/ -- Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD software to significantly improve the accuracy and speed of prostate cancer detection (CADe) and diagnosis (CADx).

Key Points: 
  • OMAHA, Neb., Aug. 8, 2022 /PRNewswire/ -- Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD software to significantly improve the accuracy and speed of prostate cancer detection (CADe) and diagnosis (CADx).
  • The tool, called ProstatID, combines artificial intelligence with traditional MRI scanning.
  • "Sadly, this has resulted in the unnecessary and premature deaths of countless numbers of men in the US alone.
  • The Omaha-based medical imaging software company's first product, ProstatID, blends AI with MRI to detect potentially cancerous lesions, assigning a cancer probability score to each, and aid physician's in the patient diagnosis.

Crowley Partners with EcoVadis for a More Transparent, Sustainable Value Chain

Retrieved on: 
Monday, August 8, 2022 - 3:00pm
Zero, Cloud, Multimedia, Johnson & Johnson, JPMorgan Chase, Carbon, Industry, Salesforce, Growth, Business, BASF, Environment, ESG, Program, Partnership, LVMH, Goal, Development, Ethics, Solution, UN, PricewaterhouseCoopers, Renewable energy, Risk management, Bridgestone, Unilever

A global provider of supply chain solutions, Crowley is the first U.S.-based company in maritime and logistics to partner with EcoVadis on its value chain solutions.

Key Points: 
  • A global provider of supply chain solutions, Crowley is the first U.S.-based company in maritime and logistics to partner with EcoVadis on its value chain solutions.
  • The partnership with EcoVadis follows Crowley's successful use of Salesforce's Net Zero Cloud technology, with PwC, to measure and analyze emissions across its full value chain.
  • EcoVadis uses indicators across 21 sustainable criteria based on four themes: environment, labor and human risks, ethics, and sustainable procurement.
  • "Crowley has taken an essential step by including the value chain in their sustainability commitments," said David McClintock, Marketing Director at EcoVadis.